Table 1.
Patients characteristics
| No of patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| Age (years) | 81 | 63 | 79 | 69 | 77 | 78 | 69 |
| Recurrence time (years) | 5.86 | 4.82 | 6.75 | 5.16 | 5.85 | 5.82 | 7.55 |
| PSADT (month) | 13.9 | 9.0 | 10.2 | 8.5 | 10.2 | 5.5 | 25.8 |
| Tumour stage (at relapse) | T2c | T3b | T2c | T2c | T3a | T2c | T3b |
| PSA at recurrence (ng/ml) | 5.11 | 6.76 | 2.80 | 5.14 | 6.32 | 5.95 | 13.00 |
| Gleason score at recurrence | 3+4 | - | 3+4 | 3+3 | 4+3 | 4+3 | 3+3 |
| GTV (cm3) | 0.61 | 1.09 | 3.48 | 5.08 | 5.75 | 10.36 | 19.93 |
| CTV (cm3) | 2.59 | 3.29 | 9.72 | 12.84 | 15.65 | 20.91 | 38.61 |
| PTV(cm3) | 6.68 | 8.13 | 22.13 | 26.67 | 30.42 | 39.47 | 64.20 |
Abbreviations: PSA = prostate-specific antigen; PSADT = prostate-specific antigen doubling time; PET-CT = Positron Emission Tomography and Computed Tomography; GTV = gross tumour volume; CTV = Clinical Target Volume; PTV = Planning Target Volume.